



ASX Announcement

May 27th 2025

Atomo secures Australian order for supply of HIV Self-Tests

- **Order worth ~\$450k for the NAPWHA run HIV Self-Test mail-out program**
- **Scale up of public health funded HIV self-testing reflects growing market for sexual health testing in the home**

SYDNEY, Australia May 27th, 2025 - Atomo Diagnostics Limited (ASX:AT1) (Atomo) is pleased to announce securing another purchase order from the National Association of People with HIV Australia (NAPWHA) for approximately \$450k worth of HIV Self-Tests. Atomo considers the revenue from this order to be material.

This order supports ongoing delivery of the national free-to-user HIV Self-Testing program run by NAPWHA. Funded by the Federal Government under new public HIV health policy announced in the May budget last year, the NAPWHA program has proven successful in increasing testing rates among key high-risk cohorts who had not been testing sufficiently or in many cases, not testing at all.

The program is supported by Grindr, the world's largest social networking app for the LGBTIQ+ community, and expansion of the program ensures availability of more HIV Self-Tests and supports growing awareness around the ability to test for free at home. The order from NAPWHA comes on the back of a large order earlier this year for HIV tests received from Thorne Harbour Health to support national scale up of a Federal Government funded Vending machine HIV Self-Testing program, reflecting the increasing use of HIV Self-Tests with the public health response to managing HIV.

Atomo CEO John Kelly said, "We are very pleased with the positive response from the community to the at-home program and we will continue to work with NAPWHA and other partners here in Australia to ensure that discrete, convenient testing is available to those wishing to know their status".



This announcement was authorised by the Board of Directors.

For more information, please contact:

John Kelly
Atomo Diagnostics
john.kelly@atomodiagnostics.com
Phone: +61 401 922 279

About Atomo

Atomo is an Australian headquartered medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market. Atomo's unique patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has commercialised several products across international markets and has supply agreements in place for testing applications targeting infectious diseases including sexual health as well as female health.

See more at www.atomodiagnostics.com